Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: A comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract

Urologia Internationalis

Volumn 85, Issue 1, 2010, Pages 47-51

  Song, Yun Seob ^a   Cho, Jin Seon ^b   Cho, Kang Su ^c   Doo, Seung Hwan ^a   Chung, Byung Ha ^c   Kim, Se Joong ^d   Yang, Won Jae ^a   Song, Ki Hak ^e   Kim, Chun Il ^f   Hong, Sung Joon ^c  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Hallym University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Ajou University   (South Korea)

^e Konyang University   (South Korea)

^f Keimyung University   (South Korea)

Author keywords

Bladder; Chemotherapy; Renal pelvis; Transitional cell carcinoma; Ureter

Indexed keywords

CISPLATIN; GEMCITABINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 77955667699     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296294     Document Type: Article

References (20)

1. Freiha F, Reese J, Torti FM: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495-499.
2. Muramaki M, Miyake H, Kurahashi T, et al: Prognostic significance of adjuvant cisplatin- based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer. Int J Urol 2008; 15: 314-318.
3. Skinner DG, Daniels JR, Russell CA, et al: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 459-464.
4. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-675.
5. Studer UE, Bacchi M, Biedermann C, et al: Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994; 152: 81-84.
6. Cummings KB: Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 1980; 7: 569-578.
7. Kwak C, Lee SE, Jeong IG, et al: Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 2006; 68: 53-57.
8. Lee SE, Byun SS, Park YH, et al: Adju - vant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int 2006; 77: 22-26.
9. Schmauz R, Cole P: Epidemiology of cancer of the renal pelvis and ureter. J Natl Cancer Inst 1974; 52: 1431-1434.
10. Williams CB, Mitchell JP: Carcinoma of the ureter - a review of 54 cases. Br J Urol 1973; 45: 377-387.
11. Adamo V, Magno C, Spitaleri G, et al: Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology 2005; 69: 391-398.
12. Als AB, Sengelov L, von der Maase H: Longterm survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. Eur Urol 2007; 52: 478-486.
13. Dogliotti L, Carteni G, Siena S, et al: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007; 52: 134-141.
14. Moore MJ, Winquist EW, Murray N, et al: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 2876-2881.
15. Stadler WM, Hayden A, von der Maase H, et al: Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002; 7: 153-157.
16. von der Maase H, Andersen L, Crino L, et al: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 1999; 10: 1461-1465.
17. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608.
18. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
19. Sternberg CN, Yagoda A, Scher HI, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461-469.
20. Lorusso V, Manzione L, De Vita F, et al: Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 2000; 164: 53-56.